Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

NCT04990557 is registered in ClinicalTrials.gov with Mahmoud Ramadan mohamed Elkazzaz as lead sponsor.

NCT NCT04990557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04990557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients
Lead sponsor
Mahmoud Ramadan mohamed Elkazzaz
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 31, 2021
Completion date
November 30, 2022
Enrollment
16 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 respiratory infection